Background: Interstitial lung diseases (ILDs) are common in patients with connective tissue diseases (CTDs). Although the diagnosis of an underlying CTD in ILD (CTD-ILD) affects both prognosis and treatment, it is sometimes difficult to distinguish CTD-ILD from chronic fibrosing interstitial pneumonia (CFIP). B cell-activating factor belonging to the tumour necrosis factor family (BAFF) plays a crucial role in B cell development, survival, and antibody production.
Methods: We examined serum levels of BAFF, surfactant protein D (SP-D), and Krebs von den Lungen-6 (KL-6) in 33 patients with CTD-ILD, 16 patients with undifferentiated CTD-ILD, 19 patients with CFIP, and 26 healthy volunteers. And we analysed the relationship between serum BAFF levels and pulmonary function, as well as the expression of BAFF in the lung tissue of patients with CTD-ILD.
Results: Serum levels of BAFF were significantly higher in CTD-ILD patients compared to healthy subjects and CFIP patients. However, there were no significant differences in serum levels of SP-D and KL-6. Furthermore, serum BAFF levels in CTD-ILD patients were inversely correlated with pulmonary function. BAFF was strongly expressed in the lungs of CTD-ILD patients, but weakly in normal lungs.
Discussion: This is the first study to demonstrate that serum BAFF levels were significantly higher in CTD-ILD patients compared to healthy subjects and CFIP patients. Furthermore, serum BAFF levels were correlated with pulmonary function. We consider that serum BAFF levels in patients with CTD-ILD reflect the presence of ILDs disease activity and severity.
Conclusion: These finding suggest that BAFF may be a useful marker for distinguishing CTD-ILD from CFIP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589966 | PMC |
| http://dx.doi.org/10.1186/s12890-015-0105-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the Severity of Connective Tissue-Related Interstitial Lung Disease Using Computed Tomography Quantitative Analysis Parameters.
J Comput Assist Tomogr
November 2024
From the Department of Medical Imaging, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin City, Jiangsu Province, China.
Objectives: The aims of the study are to predict lung function impairment in patients with connective tissue disease (CTD)-associated interstitial lung disease (ILD) through computed tomography (CT) quantitative analysis parameters based on CT deep learning model and density threshold method and to assess the severity of the disease in patients with CTD-ILD.
Methods: We retrospectively collected chest high-resolution CT images and pulmonary function test results from 105 patients with CTD-ILD between January 2021 and December 2023 (patients staged according to the gender-age-physiology [GAP] system), including 46 males and 59 females, with a median age of 64 years. Additionally, we selected 80 healthy controls (HCs) with matched sex and age, who showed no abnormalities in their chest high-resolution CT.
Longitudinal Study of Patients with Connective Tissue Disease-Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab.
Diagnostics (Basel)
November 2024
Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA.
To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up.
View Article and Find Full Text PDFAssessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.
J Thorac Dis
November 2024
Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Background: There is uncertainty with respect to the baseline tumor markers and clinical outcomes for patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The study aimed to assess the association between baseline tumor markers and progressive pulmonary fibrosis (PPF) and prognosis.
Methods: This is a prospective cohort study.
Pulmonary rehabilitation in connective tissue disease-associated interstitial lung disease: A systematic review.
Sarcoidosis Vasc Diffuse Lung Dis
December 2024
Department of Cardiopulmonary Rehabilitation, Faculty of Physical Therapy and Rehabilitation, University of Hacettepe, Ankara, Türkiye.
Article Synopsis
- Interstitial lung disease (ILD) significantly contributes to mortality in chronic lung diseases, particularly in patients with connective tissue diseases (CTD) who may not always require conventional treatment.
- A systematic review of six databases revealed that pulmonary rehabilitation (PR) benefits CTD-ILD patients in areas like lung function, quality of life, and fatigue, but evidence for improvements in muscle strength is limited.
- There is a need for more extensive research to fully understand the impact of PR on clinical outcomes for patients with CTD-ILD.
[Early-onset antibody-mediated rejection with fever as the main manifestation after bilateral lung transplantation: a case report].
Zhonghua Jie He He Hu Xi Za Zhi
December 2024
Department of Lung Transplantation, China-Japan Friendship Hospital; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences,Beijing100029, China.
Antibody-mediated rejection (AMR) is a recognized cause of allograft dysfunction in lung transplant recipients due to the presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs). Here, we reported that a 69-year-old woman with underlying connective tissue disease-associated interstitial lung disease (CTD-ILD) developed recurrent fever with elevated white blood cells, C-reactive protein (CRP) and new ground-glass opacities on chest computed tomography (CT) early after double lung transplantation. After a thorough investigation for infection, rejection and relapse of primary immune diseases, the patient was found to be panel-reactive antibody (PRA) positive and DSAs positive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!